BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
03.11.2022 - - Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization - Reported positive updated 12-month Phase 2 data ...